Oxaliplatin EP impurity B, with the CAS number 89955-85-1, is a chemical compound that is recognized as an impurity associated with the anticancer drug oxaliplatin, which is a platinum-based chemotherapy agent used primarily in the treatment of colorectal cancer. This impurity is characterized by its structural similarity to oxaliplatin, featuring a platinum center coordinated to various ligands, including oxalate and amine groups. The presence of impurities like Oxaliplatin EP impurity B is significant in pharmaceutical formulations, as they can affect the efficacy and safety of the drug. Typically, impurities are monitored and controlled during the manufacturing process to ensure compliance with regulatory standards. The characterization of such impurities often involves techniques like high-performance liquid chromatography (HPLC) and mass spectrometry to determine their identity, concentration, and potential impact on therapeutic outcomes. Understanding the properties and behavior of impurities is crucial for maintaining the quality and effectiveness of pharmaceutical products.

Oxaliplatin EP impurity B

89955-85-1: Oxaliplatin EP impurity B, with the CAS number 89955-85-1, is a chemical compound that is recognized as an impurity associated with the anticancer drug oxaliplatin, which is a platinum-based chemotherapy agent used primarily in the treatment of colorectal cancer. This impurity is characterized by its structural similarity to oxaliplatin, featuring a platinum center coordinated to various ligands, including oxalate and amine groups. The presence of impurities like Oxaliplatin EP impurity B is significant in pharmaceutical formulations, as they can affect the efficacy and safety of the drug. Typically, impurities are monitored and controlled during the manufacturing process to ensure compliance with regulatory standards. The characterization of such impurities often involves techniques like high-performance liquid chromatography (HPLC) and mass spectrometry to determine their identity, concentration, and potential impact on therapeutic outcomes. Understanding the properties and behavior of impurities is crucial for maintaining the quality and effectiveness of pharmaceutical products.

CAS 89955-85-1

Oxaliplatin EP impurity B

Oxaliplatin EP Impurity B

Ref: ST-EA-CP-O12002